Die Einträge von „Technologien aus Wien“ sind in der Projektsprache abgebildet.
Technologien aus Wien
OncoQR ML GmbH
Therapeutic vaccines for oncological, autoimmune and infectious diseasesOncoQR ML GmbH develops therapeutic vaccines for oncological, autoimmune and infectious diseases.
OncoQR has started with Pancreatic cancer (OQR100) and breast cancer (OQR200) as first indications.
OQR200 in vivo pharmacology studyFrom (passive) Checkpoint Inhibition to (active) Checkpoint Control:
The new era in battling cancer and in cancer immunotherapy is heralded by Active Checkpoint Control Immunotherapy (ACCI) developed by OncoQR ML GmbH.
We plan a dose response pharmacology study with OQR200, a novel therapeutic vaccine based on S-TIR™ technology platform, in cynomolgus monkeys. OQR200 will be indicated for the treatment of HER2/neupositive breast cancer. An initial proof of concept could be shown in a limited number of cynomolgus monkeys at one dose. Both humoral and cellular responses were induced, but the evidence for activation of HER2 specific CD8 cells was circumstantial. The proposed study will identify the most efficient dose of OQR200 and focus on the induction of HER2 specific target cell killing in vitro, using new methods. During the study the safety of the drug will be confirmed by clinical observation, clinical chemistry / hematology and histological evaluation.
AlleinstellungsmerkmalUnlike their predecessors, ACCI´s have the capability to control the immune system´s checkpoints, to activate T-cells specifically (not generally) and to selectively and specifically trigger all four naturally available tumor killing mechanisms of our immune system, everything that is required to battle the specific disease´s mechanism. In short, ACCIs are more effective, more specific, more immunogenic and much safer than any earlier approach.
Kontakt Wirtschaftsagentur Wien
Die Informations- und Vernetzungsangebote werden im Rahmen des Projektes „IC3 Innovation by Co-Operation, Co-Creation and Community Building“ aus Mitteln des Europäischen Fonds für regionale Entwicklung kofinanziert. Nähere Informationen zum IWB/EFRE-Förderprogramm